Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review examines the advances in nanostructured lipid carriers for treating hyperpigmentation but presents no new clinical results; the authors highlight their potential benefits and applications.

This review discusses perceptions and side effects of depot medroxyprogesterone acetate and emphasizes the importance of educating teens to enhance compliance; it reports no new clinical findings.

This study reports no results yet and only indicates an ongoing randomized placebo-controlled trial investigating the effects of microneedling combined with topical dutasteride solution for treating androgenetic alopecia.

This study suggests that spironolactone-loaded nanostructured lipid carriers could enhance follicular delivery and offer a more localized treatment for androgenic alopecia, potentially reducing systemic side effects.

This study found that Anovlar effectively reduced pain in severe dysmenorrhea cases and regulated cycles in oligomenorrhea patients, but some side effects and occasional treatment failures were reported.

This study suggests that a nanostructured lipid carrier formulation delivering minoxidil and latanoprost may enhance effectiveness and tolerability in treating alopecia by targeting hair follicles.

This in-silico study identified several compounds as potential Vitamin D Receptor agonists, with Dolichosterone showing the strongest binding energy.

This study found that finasteride delivered through dissolving microneedles enhanced skin drug permeation compared to films, suggesting potential for improved androgenetic alopecia treatment with fewer side effects.

This randomized trial found that diode laser achieved more favorable long-term hair removal outcomes but induced more discomfort and transient adverse effects compared to intense pulsed light in women with Fitzpatrick skin types I-IV.

This study found that finasteride-loaded nanostructured lipid carriers developed for topical application showed satisfactory size, stability, and prolonged drug release, suggesting potential for enhanced delivery in androgenic alopecia treatment.

In this study, 50 mg/day of DHEA supplementation in postmenopausal women did not significantly improve sexual function compared to a placebo over 26 weeks.

In this clinical study, low-level laser therapy using the HANDI-DOME LASER device increased hair counts by 51% compared to controls, indicating its potential as a safe and effective treatment for androgenetic alopecia in women aged 18 to 60.

Low-dose naltrexone helps improve symptoms and stabilize frontal fibrosing alopecia and lichen planopilaris.

This study suggests that a nanostructured lipid carrier formulation of minoxidil and latanoprost may effectively target hair follicles and enhance drug penetration for alopecia treatment.

In this study, an ultra-low dose combination of estradiol and dydrogesterone significantly reduced hot flushes and improved health-related quality of life among a multi-ethnic population of postmenopausal women, with no notable difference in serious adverse events compared to placebo.

Dissolvable microneedles are a promising, painless method for effective skin treatments.

This study developed a delivery platform using hyaluronic acid-based dissolvable microneedles with nanoliposomes containing kopexil and kopyrrol, which showed improved hair regeneration for treating androgenetic alopecia in vivo at lower dosages compared to minoxidil.

The medicine Diane is effective in treating hair loss, severe acne, and excessive hair growth.

In this study, researchers tested lotions containing DGLA, S-equol, and propionyl-l-carnitine on individuals with androgenic alopecia, noting a significant increase in hair count for women and a marginal increase for men after 6 months, along with improved hair cycle dynamics.

This study found that a transdermal drug delivery system using nanostructured lipid carriers and polymeric microneedles for β-sitosterol significantly enhanced hair growth in testosterone-induced alopecia rats, suggesting potential for treating androgenic alopecia.

In this study, researchers reported that both progestin-only injectable contraceptives, DMPA-IM and NET-EN, significantly decreased serum testosterone and SHBG levels among HIV-negative women in South Africa, yet this did not explain prior findings of no reduction in risky sexual behavior or sexual function.

This study observed that new trienone compounds consistently showed higher 5alpha-reductase inhibitory activity compared to corresponding dienones across various biological models.

This review discusses various microneedle technologies for long-acting drug delivery, highlighting design considerations and challenges in bringing these minimally invasive devices to market, but it reports no new clinical results.

This study found that nanostructured lipid carriers significantly improved the targeted delivery of latanoprost and minoxidil to pilosebaceous units in porcine skin, with latanoprost showing notably higher accumulation.

In this study, high-dose dutasteride significantly reduced several core symptoms of PMDD compared to placebo, supporting the role of neurosteroids in this condition.

This study found that a nanostructured lipid carrier gel containing Minoxidil and Finasteride met desired criteria for stability and performance, suggesting it may be an effective topical treatment for hair loss, especially in extreme conditions.

This study reported that an ATRA-loaded nanostructured lipid carrier gel (ATRA-NLC-Gel) improved symptoms of alopecia areata in mice by enhancing transdermal drug delivery, reducing skin irritation, and promoting hair regrowth through targeted follicle enrichment and pathway activation.